We write as professionals, activists, and public health researchers who have worked to combat AIDS and other infectious diseases in the United States and around the world for over three decades.
Worldwide governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in 2013—barely one-third of the US$2 billion that experts estimate the world must spend each year to end the global TB epidemic—according to an analysis released today by Treatment Action Group.
July 2014 Examples of media coverage: HIV “Cleared” in Two Australian Men after Bone-Marrow Transplants– Sydney Morning Herald, July 19, 2014 HIV Said Cleared in Two Bone Marrow Transplant Patients– Bloomberg News, July 18, 2014 Cancer Treatment Clears Two Australian Patients…
July 2014 Examples of media coverage: Researchers Find New Way to Kick Out HIV from Infected Cells– Time, July 21, 2014 Temple Researchers Snip Out Dormant HIV from Cells– Philadelphia Enquirer, July 22, 2014 Genome Editing Cuts Out HIV– Scientist, July 21,…
February 13, 2014 TAG, CRAG, and the TB CAB sent an open letter to AstraZeneca urging their continued investment in tuberculosis research despite the cessation of AstraZeneca’s Neglected Tropical Diseases, Tuberculosis, and Malaria Program. Read/Download the TAG, CRAG, TB CAB…
TAG, CRAG, and the TB CAB issues urgent appeal for Otsuka to initiate its long overdue compassionate use program by the end of 2013.
Cost to end deaths from childhood TB estimated to be at least US$120 million annually WASHINGTON D.C. | October 1, 2013 -- The deaths of more than 74 000 children from tuberculosis (TB) could be prevented each year through measures outlined…
For the seventh year, Treatment Action Group (TAG) and the Stop TB Partnership have published the latest investment data on the state of global tuberculosis (TB) research and development (R&D) funding.
May 24, 2012 TO: Marco Cavaleri CC: Hans-Georg Eichler European Medicines Agency 7 Westferry Circus- Canary Whar London E14 4 HB United Kingdom RE: Conducting drug-drug interaction studies for bedaquiline (TMC207) and delamanid (OPC6783) Dear Dr. Cavaleri, We wish to draw…
A follow up to the letter of May 3, 2011, regarding the steps being taken by the Coordinating Board to reduce the conflict of interest in the Stop TB Partnership’s relationship with the World Health Organization (WHO), improve transparency and accountability in the operations and activities of the Partnership, and strengthen the Partnership’s ability to fulfill its mandate.